Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 12/20 | 1.00 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.76 |
| ▸ | FAAH | O00519 | 10/20 | 0.67 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.67 |
| ▸ | FAAH2 | Q6GMR7 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2162579 | 0.86 | DAGLA (1.00) | CES1DAGLANCEH1 | |
| SCHEMBL2163442 | 0.85 | DAGLA (0.74) | CES1DAGLAFAAHNCEH1 | |
| SCHEMBL2164173 | 0.84 | DAGLA (0.72) | CES1DAGLAFAAHNCEH1 | |
| SCHEMBL2162411 | 0.83 | CES1 (1.00) | CES1DAGLAFAAHNCEH1 | |
| SCHEMBL2162627 | 0.82 | DAGLA (0.82) | CES1DAGLAFAAHNCEH1 | |
| SCHEMBL4286916 | 0.81 | CES1 (0.69) | CES1DAGLAFAAHNCEH1FAAH2 | |
| SCHEMBL2162862 | 0.80 | CES1 (1.00) | CES1DAGLAFAAHNCEH1FAAH2 | |
| SCHEMBL3193561 | 0.80 | FAAH (1.00) | CES1DAGLAFAAH | |
| SCHEMBL3193554 | 0.80 | FAAH (1.00) | CES1DAGLAFAAH | |
| SCHEMBL2162450 | 0.79 | DAGLA (0.72) | CES1DAGLANCEH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302607-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-11-29 | — | — | US | claimed |
| US-20110184026-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | claimed |
| US-20120302607-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302607-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302607-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-11-29 | — | — | US | disclosed |
| US-20110184026-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| US-20110184026-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| US-20110184026-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| WO-2009154785-A2 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009154785-A2 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302607-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | ACACA, AKR1C4, HSD17B12 | CES1 7/4885DAGLA 921/4885FAAH 16/4885 |
| US-20110184026-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | ACACA, AKR1C4, HSD17B12 | CES1 7/4885DAGLA 853/4885FAAH 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.